Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

A CNBC investigation into illegal weight loss drugs reveals a marketplace where criminals brazenly counterfeit the drugs or ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

A group representing makers of compounded drugs sued FDA over its decision to call an end to the shortage of Lilly's (LLY) ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated ...

Eli Lilly And Co. (NYSE:LLY) is ramping up its legal campaign against the compounding companies temporarily allowed to make ...

The pharmaceutical industry has seen a tremendous surge in the development of weight loss drugs, particularly GLP-1 receptor ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

We recently compiled a list of the 10 Most Promising Growth Stocks According to Hedge Funds. In this article, we are going to ...